Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cardiac Injury and Outcomes of Patients With COVID-19 in New York City

Tetsuro Maeda, MD1, Reiichiro Obata, MD1, Dahlia Rizk, DO, MPH, Toshiki Kuno, MD, PhD*

Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, NY, USA

Background

Prior studies demonstrated that elevated troponin in patients with COVID-19 was associated with increased in-hospital mortality. However, the association of cardiac injury and electrocardiogram (ECG) changes remains unclear. The aim of this study was to investigate the association of cardiac injury with ECG abnormality and with in-hospital mortality.

Methods

We conducted a retrospective cohort study of patients who were hospitalised with COVID-19 between 13 March and 31 March 2020. Those patients with troponin I measurement were included in the study and divided into those who had elevated troponin I (cardiac injury group) and those who did not (no cardiac injury group). Statistical analyses were performed to compare differences between the groups, and a multivariate logistic regression model was constructed to assess the effect of cardiac injury on in-hospital mortality.

Results

One hundred and eight-one (181) patients were included, 54 of whom were in the cardiac injury group and 127 in the no cardiac injury group. The mean age was 64.0±16.6 years and 55.8% were male. The cardiac injury group was more likely to be older, have a history of coronary artery disease, atrial fibrillation and congestive heart failure compared to the no cardiac injury group (all p<0.05); there was no difference in presence of chest pain (cardiac injury group versus no cardiac injury group: 17.0% versus 22.5%, p=0.92); the cardiac injury group had a significantly higher value of brain natriuretic peptide, procalcitonin, interleukin-6 and D-dimer (all p<0.05); they had numerically more frequent ECG abnormalities such as T wave inversion (13.2% versus 7.5%, p=0.23) and ST depression (1.9% versus 0.0%, p=0.13) although statistically not significant; they had significantly higher in-hospital mortality (42.3% versus 12.6%, p<0.001). With a multivariate logistic regression model, age (odds ratio [95% confidence interval]: 1.033 [1.002–1.065], p=0.034) and cardiac injury (3.25 [1.40–7.54], p=0.006) were independent predictors of in-hospital mortality.

Conclusions

Patients with COVID-19 with elevated troponin I had a relatively low proportion of chest pain and ECG abnormality. Cardiac injury was independently associated with in-hospital mortality.

Keywords

COVID-19 • Coronavirus • New York • Troponin

Introduction

Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global public health emergency since December 2019 [1]. Prior studies demonstrated that 12–28% of patients with COVID-19 presented with acute cardiac injury defined as elevated troponin I, and that cardiac injury was associated with increased in-hospital mortality [2–5]. Guo et al. noted that 64% of patients had
| Table 1  Baseline characteristics at admission. |
|-----------------------------------------------|
|                                                |
| No Cardiac Injury Group N=127                  | Cardiac Injury Group N=54                        | P-value |
| Age                                           | 60 [49, 71]                                     | 73.5 [67, 83] | <0.001 |
| Male                                         | 54.3% (69/127)                                  | 59.3% (32/54) | 0.54  |
| Body mass index                               | 28.7 [25.1, 33.2]                              | 28.1 [25.6, 31.9] | 0.79  |
| Race                                         | White 38.6% (49/127)                            | White 31.5% (17/54) | 0.78  |
| Black                                        | 19.7% (25/127)                                  | Black 24.1% (13/54) |       |
| Asian                                        | 10.2% (13/127)                                  | Asian 11.1% (6/54) |       |
| Others                                       | 29.1% (37/127)                                  | Others 33.3% (18/54) |       |
| Hispanic                                     | 46.3% (57/123)                                  | Hispanic 46.3% (25/54) | 0.996 |
| Symptoms                                     |                                                |                                                |
| Fever                                        | 70.9% (90/127)                                  | 42.3% (22/52) | <0.001 |
| Myalgia                                      | 19.7% (25/127)                                  | 3.8% (2/53) | 0.38  |
| Chest pain                                   | 22.8% (29/127)                                  | 17.0% (9/53) | 0.92  |
| Malaise                                      | 27.6% (35/127)                                  | 32.1% (17/53) | 0.54  |
| Sore throat                                  | 8.7% (11/127)                                   | 0.0% (0/53) | 0.027 |
| Runny nose                                   | 7.9% (10/126)                                   | 5.7% (3/53) | 0.59  |
| Dyspnoea                                     | 66.9% (85/127)                                  | 56.6% (30/53) | 0.19  |
| Cough                                        | 74.0% (94/127)                                  | 60.4% (32/53) | 0.069 |
| Sputum                                       | 25.4% (32/126)                                  | 8.7% (4/46) | 0.049 |
| Abdominal pain                               | 11.8% (15/127)                                  | 7.5% (4/53) | 0.47  |
| Nausea/Vomiting                              | 29.1% (37/127)                                  | 22.6% (12/53) | 0.37  |
| Diarrhoea                                    | 28.3% (36/127)                                  | 13.2% (7/53) | 0.030 |
| Initial Vital Signs                          |                                                |                                                |
| Temperature (°C)                              | 36.8 [36.3, 37.7]                              | 36.9 [36.2, 37.5] | 0.71  |
| Heart rate (beat/min.)                       | 97 [86, 110]                                   | 86.5 [75.5, 109] | 0.074 |
| SBP (mmHg)                                   | 133 [117, 148]                                 | 137 [109, 155] | 0.90  |
| DBP (mmHg)                                   | 77 [68, 86]                                   | 75 [64, 88] | 0.57  |
| MAP (mmHg)                                   | 94.7 [86.7, 106]                               | 93.5 [80.8, 111] | 0.97  |
| RR (/min.)                                    | 20 [18, 24]                                   | 20 [18, 24] | 0.59  |
| SpO2 (%) at room air                         | 95 [93, 98]                                   | 95 [92, 97.3] | 0.71  |
| Altered mental status                        | 5.6% (7/126)                                   | 26.4% (14/53) | <0.001 |
| Aspirin                                      | 18.9% (24/127)                                 | 41.5% (22/53) | 0.002 |
| Anticoagulation                              | 6.3% (8/127)                                   | 28.3% (15/53) | <0.001 |
| ACEI                                         | 15.0% (19/127)                                 | 24.5% (13/53) | 0.13  |
| ARB                                          | 15.1% (19/126)                                 | 26.4% (14/53) | 0.074 |
| Steroid use at home                          | 0.8% (1/126)                                   | 5.6% (3/54) | 0.047 |
| Comorbidities                                |                                                |                                                |
| Hypertension                                 | 53.5% (68/127)                                 | 90.7% (49/54) | <0.001 |
| Hyperlipidaemia                              | 36.2% (46/127)                                 | 63.0% (34/54) | 0.001 |
| DM                                           | 29.1% (37/127)                                 | 46.3% (25/54) | 0.026 |
| COPD                                         | 5.5% (7/127)                                   | 14.8% (8/54) | 0.038 |
| Asthma                                       | 11.0% (14/127)                                 | 12.5% (6/48) | 0.99  |
| CVA                                          | 3.9% (5/127)                                   | 14.8% (8/54) | 0.010 |
| PVD                                          | 4.7% (6/127)                                   | 13.0% (7/54) | <0.001 |
| Dialysis                                     | 0.8% (1/127)                                   | 9.3% (5/54) | 0.004 |
| Cirrhosis                                    | 1.6% (2/127)                                   | 3.7% (2/54) | 0.37  |
| CAD                                          | 10.0% (9/127)                                  | 44.4% (27/54) | <0.001 |
| Previous PCI                                 | 3.1% (4/127)                                   | 33.3% (18/54) | <0.001 |
| Previous CABG                                | 0.8% (1/127)                                   | 14.8% (8/54) | <0.001 |
| Previous PE/DVT                               | 7.9% (10/127)                                  | 3.7% (2/54) | 0.30  |
| History of AF                                | 3.9% (5/127)                                   | 25.9% (14/54) | <0.001 |
| Previous CHF                                  | 4.0% (5/126)                                   | 35.2% (19/54) | <0.001 |
New York City, the global epicentre of this pandemic to date.

hospital mortality in our diverse multi-ethnic population in

connection of cardiac injury with ECG abnormality as well as in-

unclear. The aim of this study was to investigate the asso-

ciation pathogenesis [6–10] rather than typical large coronary

artery occlusion; however, the exact mechanism remains

unclear. The aim of this study was to investigate the asso-
ciation of cardiac injury with ECG abnormality as well as in-

hospital mortality in our diverse multi-ethnic population in

New York City, the global epicentre of this pandemic to date.

Materials and Methods

This study was a retrospective cohort study using the data of

patients hospitalised from 13 March to 31 March 2020 with

diagnosis of COVID-19 at Mount Sinai Beth Israel, an urban

academic medical centre in downtown Manhattan [11]. Of

note, the first case of hospitalisation occurred on 13 March

2020. The study protocol was approved by the institutional

review board and conducted in accordance with the princi-

ples of the Declaration of Helsinki. Diagnosis of COVID-19

required detection of SARS-CoV-2 in a nasopharyngeal

swab specimen using reverse transcriptase polymerase chain

reaction. The decision whether to admit the patients diag-
nosed with COVID-19 was provider dependent and not

based on any specific predetermined criteria. Since our study

was a retrospective observational study, it did not require

specific tests including troponin I, ECG, or any other

treatments.

A retrospective review of patient electronic medical re-
cords was conducted mainly by two authors (R.O. and

T.M.) for demographics, comorbidities, and clinical out-

comes including troponin I and ECG findings. Regarding

ECG findings, T wave inversions were subdivided into

inferior (II, III, aVF), anterior (V1-V4), lateral (I, aVL), and

apex (V6, V6h); we also collected the data of upright T wave

in aVR [12].

Among the patients who were admitted with COVID-19,

those who had troponin I measured upon admission were

included in our study. They were divided into two groups:
those with cardiac injury (cardiac injury group) and those

without cardiac injury (no cardiac injury group). Cardiac

injury was defined as troponin I greater than 0.031 ng/ml,

which was the institutional cut-off and the 99th percentile

upper reference limit [2,13]. Laboratory data, radiographic

findings reviewed by attending radiologists, and character-

istics of hospital stay such as total length of day and ICU

stay were collected. Our institution initially used hydroxy-

chloroquine for moderate cases which was defined as radi-

logic evidence of pneumonia or oxygen saturation <94%.

Continuous variables were presented as mean±standard
deviation or median (interquartile range), as appropriate for
the data distribution; categorical variables were expressed as
percentages. The changes from baseline in continuous vari-
able were evaluated using Student’s t-test or Mann-Whitney
U test; the \( \chi^2 \) or Fisher’s exact t-test was used for analysing
categorical variables. A multivariate logistic regression
model was constructed in order to assess the association of

cardiac injury with in-hospital mortality. We included age

and troponin as variables because they have been reported as

independent predictors of mortality in patients with COVID-

19 [3,14]. Then, we performed a stepwise multivariate anal-

ysis including age and cardiac injury, and other baseline

characteristics such as hypertension, diabetes mellitus, his-
tory of coronary artery disease, congestive heart failure,

peripheral vascular disease, cerebrovascular disease, chronic

obstructive pulmonary disease, and end-stage renal disease

on dialysis. All statistical calculations and analyses were

performed using SPSS (version 24, SPSS, Armonk, NY, USA),

with p-values <0.05 considered statistically significant.

Results

Two hundred and twenty-four (224) patients were hospital-
ised with a diagnosis of COVID-19, 181 (80.8%) of whom had

evidence of myocardial ischaemia on electrocardiogram
(ECG), although only 27% of patients with cardiac injury
were assessed with ECG [4]. It is hypothesised that elevation
of troponin in patients with COVID-19 stems from direct
damage of cardiomyocytes from SARS-CoV-2 or inflamma-
tory pathogenesis [6–10] rather than typical large coronary
artery occlusion; however, the exact mechanism remains
unclear. The aim of this study was to investigate the asso-
ciation of cardiac injury with ECG abnormality as well as in-

hospital mortality in our diverse multi-ethnic population in

New York City, the global epicentre of this pandemic to date.

Materials and Methods

This study was a retrospective cohort study using the data of

patients hospitalised from 13 March to 31 March 2020 with

diagnosis of COVID-19 at Mount Sinai Beth Israel, an urban

academic medical centre in downtown Manhattan [11]. Of

note, the first case of hospitalisation occurred on 13 March

2020. The study protocol was approved by the institutional

review board and conducted in accordance with the princi-

ples of the Declaration of Helsinki. Diagnosis of COVID-19

required detection of SARS-CoV-2 in a nasopharyngeal

swab specimen using reverse transcriptase polymerase chain

reaction. The decision whether to admit the patients diag-
nosed with COVID-19 was provider dependent and not

based on any specific predetermined criteria. Since our study

was a retrospective observational study, it did not require

specific tests including troponin I, ECG, or any other

treatments.

A retrospective review of patient electronic medical re-
cords was conducted mainly by two authors (R.O. and

T.M.) for demographics, comorbidities, and clinical out-

comes including troponin I and ECG findings. Regarding

ECG findings, T wave inversions were subdivided into

inferior (II, III, aVF), anterior (V1-V4), lateral (I, aVL), and

apex (V6, V6h); we also collected the data of upright T wave

in aVR [12].

Among the patients who were admitted with COVID-19,

those who had troponin I measured upon admission were

included in our study. They were divided into two groups:
those with cardiac injury (cardiac injury group) and those

without cardiac injury (no cardiac injury group). Cardiac
injury was defined as troponin I greater than 0.031 ng/ml,

which was the institutional cut-off and the 99th percentile
upper reference limit [2,13]. Laboratory data, radiographic
findings reviewed by attending radiologists, and character-
istics of hospital stay such as total length of day and ICU
stay were collected. Our institution initially used hydroxy-
chloroquine for moderate cases which was defined as radi-
logic evidence of pneumonia or oxygen saturation <94%.

Continuous variables were presented as mean±standard
deviation or median (interquartile range), as appropriate for
the data distribution; categorical variables were expressed as
percentages. The changes from baseline in continuous vari-
able were evaluated using Student’s t-test or Mann-Whitney
U test; the \( \chi^2 \) or Fisher’s exact t-test was used for analysing
categorical variables. A multivariate logistic regression
model was constructed in order to assess the association of
cardiac injury with in-hospital mortality. We included age

and troponin as variables because they have been reported as

independent predictors of mortality in patients with COVID-

19 [3,14]. Then, we performed a stepwise multivariate anal-

ysis including age and cardiac injury, and other baseline

characteristics such as hypertension, diabetes mellitus, his-
tory of coronary artery disease, congestive heart failure,

peripheral vascular disease, cerebrovascular disease, chronic

obstructive pulmonary disease, and end-stage renal disease

on dialysis. All statistical calculations and analyses were

performed using SPSS (version 24, SPSS, Armonk, NY, USA),

with p-values <0.05 considered statistically significant.

Results

Two hundred and twenty-four (224) patients were hospital-
ised with a diagnosis of COVID-19, 181 (80.8%) of whom had

Table 1 (continued).

|                        | No Cardiac Injury Group N=127 | Cardiac Injury Group N=54 | P-value |
|------------------------|------------------------------|---------------------------|---------|
| History of cancer      | 9.4% (12/127)                | 5.6% (3/54)               | 0.39    |
| HIV                    | 4.7% (6/127)                 | 5.6% (3/54)               | 0.81    |
| Smoker                 |                              |                           |         |
| Never smoker           | 73.8% (93/126)               | 58.8% (30/51)             | 0.065   |
| Former smoker          | 22.2% (28/126)               | 39.2% (20/51)             |         |
| Current smoker         | 4.0% (5/126)                 | 2.0% (1/51)               |         |

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RR, respiratory rate; SIRS, systemic inflammatory response syndrome; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PVD, peripheral vascular disease; CKD, chronic kidney disease; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PE/DVT, pulmonary embolism/deep vein thrombosis; AF, atrial fibrillation; CHF, congestive heart failure; HIV, human immunodeficiency virus.
### Table 2  Baseline laboratory findings.

|                               | No Cardiac Injury Group N=127 | Cardiac Injury Group N=54 | P-value |
|-------------------------------|-------------------------------|---------------------------|---------|
| **Complete blood count**      |                               |                           |         |
| White blood cell, K/µL        | 7.0 [4.9, 9.2]                | 7.5 [5.5, 10.2]           | 0.28    |
| Neutrophil, K/µL              | 5.2 [3.3, 7.1]                | 5.5 [3.9, 7.2]            | 0.31    |
| Lymphocyte, K/µL              | 1.0 [0.8, 1.4]                | 0.80 [0.63, 1.38]         | 0.076   |
| Haemoglobin, g/dL             | 14.1 [13.1, 15.2]             | 12.6 [11.0, 13.6]         | <0.001  |
| Platelet, K/µL                | 177 [133, 233]                | 148 [123, 171]            | 0.005   |
| **Biochemistry panel**        |                               |                           |         |
| Glucose, mg/dL                | 116 [99, 149]                 | 122 [103.8, 154]          | 0.50    |
| BUN, mg/dL                    | 15 [11, 22]                   | 26 [17.8, 43]             | <0.001  |
| Creatinine, mg/dL             | 0.9 [0.71, 1.13]              | 1.41 [0.9, 2.16]          | <0.001  |
| AST, U/L                      | 41.5 [28, 60.3]               | 44 [27, 68]               | 0.82    |
| ALT, U/L                      | 31.5 [19.3, 49.8]             | 26 [19, 44.5]             | 0.25    |
| Total bilirubin, mg/dL        | 0.5 [0.4, 0.7]                | 0.6 [0.4, 0.9]            | 0.030   |
| Albumin, g/dL                 | 3.4 [3.1, 3.7]                | 3.2 [2.8, 3.6]            | 0.003   |
| LDH, U/L                      | 374 [271, 509]                | 409 [380, 545]            | 0.15    |
| CPK, U/L                      | 174 [65, 376]                 | 140 [69, 441]             | 0.83    |
| **Coagulation**               |                               |                           |         |
| PT-INR                        | 1.0 [1.0, 1.1]                | 1.1 [1.0, 1.3]            | 0.004   |
| APTT (s)                      | 31.4 [28.4, 36.2]             | 33.3 [29.6, 38.4]         | 0.27    |
| D-dimer, µg/mL                | 0.82 [0.58, 1.33]             | 2.03 [0.97, 3.08]         | <0.001  |
| **Inflammation marker**       |                               |                           |         |
| CRP or hsCRP, mg/L            | 70.7 [37.8, 141]              | 99.3 [42.8, 167]          | 0.21    |
| Procalcitonin, ng/mL          | 0.11 [0.05, 0.24]             | 0.42 [0.11, 0.74]         | <0.001  |
| Ferritin, ng/mL               | 525 [303, 1,315]              | 670 [253, 1,428]          | 0.66    |
| IL-6, pg/L                    | 47.1 [22.1, 110]              | 87.9 [48.0, 140]          | 0.020   |
| **Others**                    |                               |                           |         |
| pH (venous blood gas)         | 7.41 [7.38, 7.44]             | 7.40 [7.33, 7.42]         | 0.026   |
| Lactate, mmol/L               | 1.31 [1.08, 1.80]             | 1.50 [1.15, 1.95]         | 0.11    |
| BNP, pg/mL                    | 13.6 [10.0, 40.4]             | 191 [78, 720]             | <0.001  |
| Troponin I, ng/mL             | 0.01 [0.01, 0.01]             | 0.096 [0.059, 0.14]       | <0.001  |
| **ECG**                       |                               |                           |         |
| AF                            | 1.7% (2/119)                  | 13.2% (7/53)              | 0.002   |
| PAC                           | 2.5% (3/120)                  | 5.7% (3/53)               | 0.30    |
| PVC                           | 0.0% (0/120)                  | 13.2% (7/53)              | <0.001  |
| CRBBB                         | 3.3% (4/120)                  | 11.3% (6/53)              | 0.038   |
| CLBBB                         | 0.8% (1/120)                  | 3.8% (2/53)               | 0.172   |
| TWI                           | 7.5% (9/120)                  | 13.2% (7/53)              | 0.23    |
| TWI inferior                  | 0.8% (1/120)                  | 3.8% (2/53)               | 0.17    |
| TWI anterior                  | 5.8% (7/120)                  | 1.9% (1/53)               | 0.26    |
| TWI lateral                   | 1.7% (2/120)                  | 7.5% (4/53)               | 0.051   |
| TWI apex                      | 0.0% (0/120)                  | 5.7% (3/53)               | 0.009   |
| Upright T wave in aVR         | 0.0% (0/120)                  | 0.0% (0/53)               | -       |
| ST depression                 | 0.0% (0/120)                  | 1.9% (1/53)               | 0.13    |
| ST elevation in aVR           | 0.0% (0/120)                  | 0.0% (0/53)               | -       |
| Chest X-ray                   | 96.9% (123/127)               | 98.1% (53/54)             | 1.00    |
| Multifocal pneumonia          | 59.3% (73/123)                | 56.6% (30/53)             | 0.73    |
| Pleural effusion              | 4.1% (5/123)                  | 17.0% (9/53)              | 0.006   |

Abbreviations: BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CPK, creatine kinase; PT-INR, prothrombin time-international normalised ratio; APTT, activated partial thromboplastin time; CRP, C-reactive protein; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; BNP, B type natriuretic peptide; ECG, electrocardiogram; AF, atrial fibrillation; CRBBB, complete right bundle branch block; CLBBB, complete left bundle branch block; PAC, premature atrial contraction; PVC, premature ventricular contraction; TWI, T wave inversion.
measurement of troponin I upon admission and were included in the study. Among the 181 patients, the mean age was 64.0 ± 16.6 and 55.8% were male; 36.4% were Caucasian, 21.0% were African American, 43.9% were Hispanic. Fifty-four (54) patients were categorised into the cardiac injury group and 127 into the no cardiac injury group. Detailed baseline characteristics are shown in Table 1. The cardiac injury group was more likely to be older and have hypertension, and end-stage renal disease on dialysis, coronary artery disease as a previously known comorbidity (all p-value < 0.05). Prior coronary revascularisation and known atrial fibrillation and congestive heart failure were also more frequently compared to the no cardiac injury group (all p-value < 0.05). Notably, both groups had non-significantly different, relatively low rates of chest pain (cardiac injury group versus no cardiac injury group: 17.0% versus 22.5%, p=0.92).

Table 2 describes baseline laboratory, ECG and radiographic findings. The cardiac injury group had significantly higher blood urea nitrogen, creatinine, creatine kinase, brain natriuretic peptide, D-dimer and inflammatory markers such as procalcitonin and interleukin-6, and lower haemoglobin compared to the no cardiac injury group (all p-value < 0.05). Electrocardiograph was obtained in 95.6% of individuals. Electrocardiograph findings including T wave inversion and ST depression appeared numerically more frequent in the cardiac injury group but were not statistically significantly different (cardiac injury group versus no cardiac injury group; T wave inversion: 13.2% versus 7.5%, p=0.23; ST depression: 1.9% versus 0.0%, p=0.13). There was no significant difference of multifocal pneumonia on chest X-ray in both groups (cardiac injury group versus no cardiac injury group: 56.6% versus 59.3%, p=0.73).

Table 3 shows in-hospital treatment and outcomes. 32.1% of patients in the cardiac injury group required invasive mechanical ventilation (18.2% of total cohort). The cardiac injury group had significantly higher in-hospital mortality than the no cardiac injury group (42.3% versus 12.6%, p < 0.001). Only one patient died with ventricular fibrillation/pulseless ventricular tachycardia in the overall group (4.5% of deceased patients among cardiac injury, 1.9% of cardiac injury).

The multivariate logistic regression analysis with stepwise method was performed with age, cardiac injury, hypertension, diabetes mellitus, history of coronary artery disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, and end-stage renal disease on dialysis as variables. The final variables were age and cardiac injury. Age (odds ratio (OR) [95% confidence interval (CI)]: 1.033 [1.002–1.065], p=0.034) and cardiac injury (3.25 [1.40–7.54], p=0.006) were both independent predictors of in-hospital mortality.

Discussion

The salient findings of this cohort study are the following: 1) the cardiac injury group had higher rates of prior cardiac history as compared to the no cardiac injury group and also had higher inflammatory markers and D-dimer; 2) the cardiac injury group had a relatively low proportion of chest...
pain and ECG abnormality such as T wave inversion and ST depression; and 3) the cardiac injury group had a mortality rate of 42.3% and cardiac injury was an independent predictor of in-hospital mortality.

As of 12 April 2020, New York City has been named the epicentre of the COVID-19 global pandemic and better understanding of the disease was highly desired [15]. Most of the initial clinical data of COVID-19 came from China, including those regarding cardiac injury, which may not be applicable to a population with different ethnic and social backgrounds. In our study, the cardiac injury group was more likely to have a history of cardiovascular disease, similar to a prior study by Guo et al. [4]. That study also revealed that the cardiac injury group had a higher rate of coronary artery disease, and that a combination of cardiovascular disease and cardiac injury was associated with greater mortality. Our study validates that cardiac injury is a predictor of in-hospital mortality even in a diverse multicultural population. Several studies have reported the association of elevated troponin and poor outcomes in patients with COVID-19 [16], but there have not been robust reports of ECG findings to our knowledge. Our study contained a detailed analysis of presenting symptoms and ECG findings, and did not show statistically significant difference in presence of chest pain or ECG changes; although T wave inversion and ST depression appeared numerically more frequent in the cardiac injury group. The small sample may have failed to show an increase in large vessel coronary artery disease and ischaemia, but this result suggests that cardiac injury with COVID-19 may be from other mechanisms. For instance, there are reports of myocarditis caused by direct myocardial invasion by SARS-CoV-2 and of takotsubo cardiomyopathy [6,9,17,18]; also, cytokine storm caused by systemic inflammation leading to coagulopathy, which may contribute to thrombus formation and ischaemia in microcoronary circulation [19].

There are several limitations in our study. This study was conducted in a single centre hospital with a relatively small sample size with approximately 80% of total consecutive hospitalised patients with a measurement of troponin I. Despite adjustment, we could not eliminate all unmeasured confounding factors. Moreover, higher rates of chronic kidney disease in cardiac injury group might affect elevation of troponin I [20]. Nonetheless, our study shows detailed information regarding symptoms and ECG abnormalities among patients with COVID-19.

**Conclusion**

Patients with COVID-19 with elevated troponin I had relatively low proportion of chest pain and ECG abnormality, which might suggest cardiac injury is just a reflection of systemic inflammation and coagulopathy due to COVID-19. Cardiac injury was an independent predictor of in-hospital mortality.

**Disclosures**

There are no conflicts of interest to disclose.

**Funding Sources**

None.

**References**

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33.
[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
[3] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.
[4] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811–8.
[5] Kuno T, Takahashi M, Obata R, Maeda T. Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City. Am Heart J. 2020;226:24–5.
[6] Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819–24.
[7] Siripanthong B, Nazarban S, Muser D, Deo R, Santangeli P, Khanji M, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17:1463–71.
[8] Coyle J, Iginomwanwahia E, Sanchez-Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID-19 Myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. JACC Case Rep. 2020;13:913–6.
[9] Cizgici AY, Zencirikran Agus H, Yildiz M. COVID-19 myopericarditis: it should be kept in mind in today’s conditions. Am J Emerg Med. 2020;38:1547.e5–6.
[10] Paul JF, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging. 2020;21:776.
[11] Jangi S. Facing uncertainty—dispatch from Beth Israel Medical Center, Manhattan. N Engl J Med. 2012;367:2267–9.
[12] Kosuge M, Ebina T, Hibi K, Tsukahara K, Iwahashi N, Gohbara M, et al. Cardiovascular comorbidities, factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
[13] Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333.
[14] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors of mortality of adult inpatients with COVID-19 in Wuhan, China. JAMA. 2020;323:1349–57.
[15] Hartikainen TS, Sorensen NA, Haller PM, Gobling A, Lehmacher J, Zeller T, et al. Clinical application of the 4th Universal Definition of Myocardial Infarction. Eur Heart J. 2020;41:2209–16.
[16] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a prospective cohort study. Lancet. 2020;395:1054–62.
[17] Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333.
[18] Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranspe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76:57.
[19] Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Scuotti F, Botta Z, et al. Myocardial localization of coronavirus in COVID-19 cardiac shock. Eur J Heart Fail. 2020;22:911–5.
[20] Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, et al. Takotsubo syndrome in the setting of COVID-19. JACC Case Rep. 2020;2:1321–5.
[21] Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116–21.
[22] Pang L, Wang Z, Zhao ZL, Guo Q, Huang CW, Du JL, et al. Associations between estimated glomerular filtration rate and cardiac biomarkers. J Clin Lab Anal. 2020;34:e23336.